Canaccord lowered the firm’s price target on 2seventy Bio to $12 from $20 and keeps a Buy rating on the shares. The firm said ABECMA revenues could return to growth in 2024, assuming FDA approval in 3L Multiple Myeloma, but competition will continue to be challenging.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSVT:
- 2Seventy Bio, Inc. (TSVT) Q4 Earnings Cheat Sheet
- 2seventy bio and BMS Schedule FDA Panel for Abecma
- Bristol Myers and 2seventy Bio’s application for Abecma to be reviewed by FDA
- 2seventy Bio upgraded to Outperform at Leerink on acquisition potential
- 2seventy Bio upgraded to Outperform from Market Perform at Leerink
